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Abstract
Introduction Vascular endothelial growth factor (VEGF) plays a
central role in promoting angiogenesis and is over-expressed in
breast cancer. At least four polymorphisms in the VEGF gene
have been associated with changes in VEGF expression levels:
-2578C/A, -1154G/A and -634G/C are all located in the
promoter region; and +936C/T is located in the 3'-untranslated
region.
Method We examined the association between these four
VEGF  polymorphisms and risk for breast cancer among
postmenopausal women in CPS-II (Cancer Prevention Study II)
Nutrition Cohort. This cohort was established in 1992 and
participants were invited to provide a blood sample between
1998 and 2001. Included in this analysis were 501
postmenopausal women who provided a blood sample and
were diagnosed with breast cancer between 1992 and 2001
(cases). Control individuals were 504 cancer-free
postmenopausal women matched to the cases with respect to
age, race/ethnicity, and date of blood collection (controls).
Results We found no association between any of the
polymorphisms examined and overall breast cancer risk.
However, associations were markedly different in separate
analyses of invasive cancer (n = 380) and in situ cancer (n =
107). The -2578C and -1154G alleles, which are both
hypothesized to increase expression of VEGF, were associated
with increased risk for invasive breast cancer (odds ratio [OR]
1.46, 95% confidence interval [CI] 1.00–2.14 for -2578 CC
versus AA; OR 1.64, 95% CI 1.02–2.64 for -1154 GG versus
AA) but they were not associated with risk for in situ cancer. The
+936C allele, which is also hypothesized to increase VEGF
expression, was not clearly associated with invasive breast
cancer (OR 1.21, 95% CI 0.88–1.67 for +936 CC versus TT/
CT), but it was associated with reduced risk for in situ cancer
(OR 0.59, 95% CI 0.37–0.93 for CC versus TT/CT). The -634
C/G polymorphism was not associated with either invasive or in
situ cancer.
Conclusion Our findings provide limited support for the
hypothesis that the -2578C and -1154G VEGF  alleles are
associated with increased risk for invasive but not in situ breast
cancer in postmenopausal women.
Introduction
Angiogenesis, the development of new blood vessels, is
required for the growth of microscopic cancers into larger,
clinically relevant tumors [1]. Vascular endothelial growth fac-
tor (VEGF) is believed to play a central role in angiogenesis
through a variety of mechanisms, including effects on endothe-
lial cell proliferation, survival, and migration [2]. VEGF is over-
expressed even in early stage breast cancers [3], and high
tumor VEGF expression is associated with both increased
tumor microvessel density and increased risk for breast cancer
recurrence [4-7].
The VEGF gene includes at least four polymorphisms that are
relatively common and may influence VEGF expression. Three
of these polymorphisms are located in the promoter region at
-2578C/A (rs699947), -1154G/A (rs1570360) and -634G/C
(rs2010963), relative to the translation start site. The -2578C,
-1154G and -634C alleles have all been associated with
increased VEGF expression [8,9]. The -1154G allele has also
been associated with melanoma thickness [10], prostate can-
cer incidence and progression [11], and high VEGF expres-
sion within lung tumors [12]. In addition to these promoter
region polymorphisms, the C allele of a common polymor-
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phism located in the 3' untranslated region (+936C/T;
rs3025039) is associated with substantially increased serum
VEGF levels [13,14].
To our knowledge, three previous studies [14-16] have exam-
ined the association between VEGF  polymorphisms and
breast cancer risk. An Austrian study [14], including 500
cases and 500 controls, found the +936C allele to be associ-
ated with substantially increased risk for breast cancer (odds
ratio [OR] 2.0, 95% confidence interval [CI] 1.4–2.6). A
smaller study from the UK [15], including 134 cases and 263
controls, found no statistically significant association between
the -1154G/A polymorphism and breast cancer risk. Recently,
results were published from a case-control study including
571 familial breast cancer cases from Poland and Germany
and 974 unselected breast cancer cases from Sweden [16].
That study examined both the three promoter region polymor-
phisms (-2578C/A, -1154G/A, and -634G/C) and the
+936C/T polymorphism. There was no suggestion of any
association between any of these polymorphisms and breast
cancer risk, although -1154G/A was examined using only the
familial cases and -634G/C was examined using only the
unselected Swedish cases. However, there was some evi-
dence that the promoter region polymorphisms might be asso-
ciated with cancer progression. In analyses conducted among
cancer cases, the -2578C allele was associated with signifi-
cantly higher histologic grade, and the -634C allele was asso-
ciated with both significantly higher histologic grade and
increased tumor size.
To explore further the role played by potentially functional
VEGF polymorphisms, we examined the association between
the three promoter region polymorphisms (-2578C/A, -
1154G/A and -634G/C) and a 3'-untranslated region poly-
morphism (+936C/T) and risk for incident breast cancer using
postmenopausal cases and controls from the CPS-II (Cancer
Prevention Study II) Nutrition Cohort.
Materials and methods
Study population
Women included in the analysis were participants in the CPS-
II Nutrition Cohort [17]; the CPS-II is a prospective study of
cancer incidence including approximately 184,000 US men
and women, established by the American Cancer Society. At
enrollment into the Nutrition Cohort in 1992 or 1993, all par-
ticipants completed a self-administered questionnaire that
included questions on demographics, medical and reproduc-
tive history, and lifestyle factors. Most participants were age
50–74 years at the time of enrollment. Beginning in 1997, fol-
low-up questionnaires were sent to cohort members every 2
years to update exposure information and to ascertain newly
diagnosed cancers. Incident cancers reported on question-
naires were verified through medical records, linkage with
state cancer registries, or death certificates. The recruitment,
characteristics, and follow up of the CPS-II Nutrition Cohort
are described in detail elsewhere [17].
From June 1998 through June 2001, participants in the CPS-
II Nutrition Cohort were invited to provide a blood sample.
After obtaining informed consent, blood samples were col-
lected from 39,371 participants, including 21,963 women.
Among postmenopausal women who had provided a blood
sample, we initially identified 509 women who had been diag-
nosed with breast cancer between 1992 and 2001 and had
not been diagnosed with any other cancer (other than non-
melanoma skin cancer; cases). Most of these cases (n = 328)
were diagnosed before they provided a blood sample. Sixty-
four per cent of these prevalent cases provided a blood sam-
ple within 2 years of their diagnosis date, although the maxi-
mum time between diagnosis and blood draw was 7.6 years.
For each case, we randomly selected one control from among
the postmenopausal women who had provided a blood sam-
ple and were cancer free at the time of the case diagnosis.
Each control was individually matched to a case with respect
to birth date (± 6 months), date of blood collection (± 6
months), and race/ethnicity (white, African-American, His-
panic, Asian, other/unknown). Eight of the cases and five of
the controls initially selected were later excluded because
genotyping failed for all polymorphisms examined, because on
more detailed review they were found not to have been truly
postmenopausal or not to have had breast cancer (if a case),
or if no DNA sample was available. A total of 501 cases and
504 controls remained for analysis.
Laboratory methods
DNA was extracted from buffy coat and genotyping assays
were performed using TaqMan (Applied Biosystems, Foster
City, CA, USA). Genotyping was performed by laboratory per-
sonnel blinded to case-control status and 10% blind dupli-
cates were randomly interspersed with the case-control
samples for quality control. Concordance for these quality
control samples was 100%. The genotyping success rate was
95% or greater for each of the polymorphisms examined. The
genotype distribution among controls was in Hardy-Weinberg
equilibrium (P > 0.05) for all of the polymorphisms examined.
Statistical analysis
In preliminary analyses using only matched pairs, results were
similar when we used a matched pair analysis and when we
adjusted for the matching variables. To make use of informa-
tion from all genotyped cases and controls, we therefore cal-
culated ORs using a conditional logistic regression model that
adjusted for each of the matching variables rather than using
a matched pair analysis. All models are adjusted for birth year
(in single year categories), blood collection date (in single year
categories), and race/ethnicity (white, African-American, His-
panic, Asian, or other/unknown).Available online http://breast-cancer-research.com/content/8/2/R22
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Table 1
Odds ratios for breast cancer incidence by VEGF genotype.
Polymorphism Controls (n = 504) All casesa (n = 501) In situ cases (n = 107) Invasive cases (n = 380)
n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
-2578C/A (rs 699947)
AA 130 (26.3 %) 114 (22.9%) 1.00 (ref.) 31 (29.0 %) 1.00 (ref.) 81 (21.4 %) 1.00 (ref.)
AC 236 (47.7%) 245 (49.2%) 1.18 (0.86–1.61) 53 (49.5%) 0.92 (0.55–1.52) 184 (48.7%) 1.24 (0.88–1.74)
CC 129 (26.1%) 139 (27.9%) 1.25 (0.88–1.77) 23 (21.5%) 0.68 (0.37–1.24) 113 (29.9%) 1.46 (1.00–2.14)
P (for trend) 0.21 0.21 0.049
-1154G/A (rs 1570360)
AA 57 (11.6 %) 51 (10.3%) 1.00 (ref.) 17 (16.0%) 1.00 (ref.) 33 (8.8%) 1.00 (ref.)
AG 227 (46.1%) 208 (42.0%) 1.01 (0.66–1.55) 48 (45.3%) 0.66 (0.34–1.25) 152 (40.5%) 1.14 (0.70–1.84)
GG 208 (42.3%) 236 (47.7%) 1.29 (0.84–1.97) 41 (38.7%) 0.62 (0.32–1.20) 190 (50.7%) 1.64 (1.02–2.64)
P (for trend) 0.083 0.24 0.007
-634G/C (rs 201963)
GG 232 (46.4 %) 221 (44.7%) 1.00 (ref.) 56 (52.8%) 1.00 (ref.) 161 (42.9%) 1.00 (ref.)
CG 221 (44.2%) 222 (44.9%) 1.05 (0.80–1.37) 39 (36.8%) 0.73 (0.46–1.15) 174 (46.4%) 1.13 (0.85–1.50)
CC 47 (9.4%) 52 (10.5%) 1.18 (0.76–1.83) 11 (10.4%) 0.88 (0.42–1.84) 40 (10.7%) 1.27 (0.79–2.05)
P (for trend) 0.47 0.35 0.26
+936C/T (rs 3025039)
TT or CTb 126 (26.3%) 128 (26.2%) 1.00 (ref.) 39 (38.2%) 1.00 (ref.) 86 (23.1%) 1.00 (ref.)
CC 353 (73.7%) 360 (73.8%) 1.02 (0.76–1.36) 63 (61.8%) 0.59 (0.37–0.93) 286 (76.9%) 1.21 (0.88–1.67)
P (for trend) 0.73 0.052 0.20
Blood prediction scorec
0–1 31 (6.5 %) 38 (7.8 %) 1.00 (ref.) 11 (10.9 %) 1.00 (ref.) 27 (7.3 %) 1.00 (ref.)
2 157 (33.0%) 131 (27.0%) 0.72 (0.42–1.22) 38 (37.6%) 0.75 (0.34–1.64) 90 (24.3%) 0.68 (0.38–1.22)
3 198 (41.6%) 214 (44.1%) 0.92 (0.55–1.55) 39 (38.6%) 0.56 (0.25–1.24) 166 (44.7%) 0.99 (0.57–1.75)
4 90 (18.9%) 102 (21.0%) 0.99 (0.57–1.72) 13 (12.9%) 0.39 (0.15–0.98) 88 (23.7%) 1.22 (0.67–2.23)
Trend OR (95% CI)d 1.09 (0.94–1.26) 0.73 (0.57–0.96) 1.20 (1.02–1.41)
P (for trend) 0.28 0.021 0.030
Odds ratios (ORs) are adjusted for birth-year, year of blood draw, and race/ethnicity. aIncludes 14 cases of unknown stage. bThe TT genotype was 
carried by eight controls and six cases (two in situ cases and four invasive cases). cSum of -2578C and +936C alleles, which have each been 
associated with increased blood levels of vascular endothelial growth factor. dOR associated with a 1-point increase in the blood prediction score. 
CI, confidence interval;
We examined the association between breast cancer risk and
each VEGF polymorphism (-2578C/A, -1154G/A, -634G/C,
and +936C/T). To simplify interpretation of results, we used
the low expression allele of each polymorphism as the referent
group when calculating ORs. Because the T allele of the
+936C/T polymorphism was uncommon (allele frequency of
14% among controls), we combined TT and CT genotypes
when calculating ORs. P  values for trend were calculated
using the number of high VEGF expression alleles (0, 1, or 2).
We also examined an additional polymorphism, -1497T/C
(rs833061), but found this analysis to be uninformative
because alleles for -1497T/C were almost perfectly correlated
with those for -2578C/A, for which there is more evidence of
functional importance.
Because we hypothesized that combined effects of VEGF pol-
ymorphisms might be important, we examined the association
between breast cancer risk and a VEGF 'blood prediction
score', that we created a priori (before any genotyping results
were seen). The +936C allele has been associated with
increased VEGF blood levels [13,14]. In addition, individuals
with promoter region haplotypes that included the -2578CBreast Cancer Research    Vol 8 No 2    Jacobs et al.
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allele appeared to have substantially increased blood VEGF
levels in one study [8], although analyses of individual polymor-
phisms were not presented. We therefore defined each indi-
vidual's blood prediction score as the sum of their +936C and
-2578C alleles.
Because promoter region polymorphisms in the VEGF gene
are in linkage disequilibrium [8], we examined associations
between breast cancer risk and haplotypes defined by the
three promoter region polymorphisms (-2578C/A, -1154G/A,
and -634G/C). Haplotype frequencies were estimated using
the partition-ligation expectation-maximization algorithm imple-
mented in the program tagSNPS [18]. Estimated haplotype
frequencies were all within 0.005 of an integer value (0, 1, or
2), and so we rounded the estimated haplotype frequencies to
the nearest integer. We tested the global hypothesis of no
association between the measured promoter haplotypes and
breast cancer risk using a likelihood ratio test comparing a
model that included variables for each haplotype with a model
that did not include these variables. We also examined asso-
ciations between breast cancer risk and promoter diplotypes,
defined by the combination of the two haplotypes carried by
each participant.
Results
Breast cancer cases and controls in this analysis were pre-
dominantly white (approximately 98% of both cases and con-
trols) and middle aged or elderly at time of diagnosis (median
age 68 years). Table 1 shows the association between each
individual  VEGF  polymorphism and risk for breast cancer.
Because we hypothesized that VEGF polymorphisms may play
a role in breast cancer progression, results are shown sepa-
rately for in situ breast cancer and invasive breast cancer, as
well as for all breast cancers combined. None of the polymor-
phisms were statistically significantly associated with all
breast cancers combined. However, results differed markedly
for in situ and invasive breast cancer. For in situ breast cancer,
the high expression alleles of all four polymorphisms were
associated with ORs below 1, although only the +936C allele
was associated with a statistically significant reduction in risk
(OR 0.59, 95% CI 0.37–0.93 for +936 CC versus CT/TT). In
contrast, for invasive breast cancer ORs were above 1 for the
high expression alleles of all four polymorphisms, although only
the -2578C and -1154G alleles were associated with statisti-
cally significant increases in risk (OR 1.46, 95% CI 1.00–2.14
for -2578 CC versus AA; OR 1.64, 95% CI 1.02–2.64 for -
1154 GG versus AA). These associations did not appear to
differ for regional or distant breast cancers compared with only
locally invasive breast cancers (results not shown), although
there were few regional or distant cases (n = 71). Results did
not appear to differ by tumor size or grade (results not shown),
although information on tumor size was available for only 38%
of in situ cancer cases. Results did not change meaningfully
when we adjusted for breast cancer risk factors in this study
population, including use of hormone replacement therapy,
history of breast cysts, family history of breast cancer, parity,
and adult weight gain.
Table 1 also shows results for the blood prediction score, an
a priori measure that combined information from two polymor-
phisms (-2578C/A and +936C/T) that are associated with
VEGF blood levels (see Materials and method, above). The
blood prediction score was not associated with risk for all
breast cancers combined. However, the blood prediction
score was associated with both significantly reduced risk for
in situ breast cancer (OR 0.73, 95% CI 0.57–0.96 per 1 point
increase in the blood prediction score) and significantly
increased risk for invasive breast cancer (OR 1.20, 95% CI
1.02–1.41 per 1 point increase in blood prediction score).
The three promoter region polymorphisms we examined are in
linkage disequilibrium [8]. We therefore examined haplotypes
defined by these three polymorphisms (-2578/-1154/-634;
Table 2). Only four haplotypes were identified, the same hap-
lotypes that were reported in a previous study [8]. Haplotype
results are shown only for invasive breast cancer because
associations between individual polymorphisms appeared to
be different for invasive and in situ cancer, and there were rel-
atively few in situ cases (n = 107). The AAG haplotype, the
only haplotype that did not include the 1154G allele, was
associated with reduced risk (OR 0.62, 95% CI 0.38–1.00 for
two copies versus none). The global test of association
between measured promoter haplotypes and breast cancer
risk (see Materials and method, above) yielded a P value of
0.04. There was a moderate degree of correlation between the
three promoter region polymorphisms. Among controls in our
study,  r2  (correlation coefficient squared) was 0.55 for -
2578C/A and -1154G/A, 0.49 for -2578C/A and -634G/C,
and 0.27 for -1154G/A and -634G/C. Among controls in our
study, the linkage disequilibrium coefficient (D') was 0.99 for -
2578C/A and -1154G/A, 1.00 for -2578C/A and -634G/C,
and 1.00 for -1154G/A and -634G/C.
In addition to examining haplotypes, we also examined the
association between VEGF promoter diplotypes and risk for
invasive breast cancer (results not shown). No diplotype was
statistically significantly associated with risk for invasive breast
cancer, although ORs were greater than 1.4 for each of the six
diplotypes that included two copies of the -1154G allele com-
pared with the AAG/AAG diplotype (the diplotype hypothe-
sized to have the lowest expression and used as the referent
group).
Discussion
In this study, alleles of two promoter region polymorphisms
hypothesized to increase VEGF expression and a combined
measure of high VEGF expression alleles (the blood prediction
score) were associated with increased risk for invasive breast
cancer. In contrast, the blood prediction score was associated
with reduced risk for in situ breast cancer. Although theseAvailable online http://breast-cancer-research.com/content/8/2/R22
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results could be due to chance, it is biologically plausible that
increased VEGF expression could accelerate the progression
from in situ to invasive breast cancer. Whereas in situ breast
cancers are by definition confined to narrow ducts and may
not require angiogenesis, the development of tumors beyond
1–2 mm in diameter is believed to require angiogenesis [1].
When interpreting results it should be noted that the -2578C/
A and -1154G/C polymorphisms that were associated with
increased risk for invasive breast cancer are in linkage disequi-
librium. Therefore, the associations of these two polymor-
phisms with breast cancer risk are not statistically
independent. In addition, the AAG promoter haplotype, which
was associated with significantly reduced risk for invasive can-
cer, was the only haplotype that did not include the -1154G
allele. Therefore the reduced risk associated with the AAG
promoter haplotype and the increased risk associated with -
1154G allele are simply different ways to describe the same
underlying association.
Our results differ from those of the largest study of VEGF pol-
ymorphisms and breast cancer to date, a recent European
study that included both unselected cases of breast cancer
from Sweden, and a separate group of familial breast cancer
cases, predominantly from Poland [19]. This European study
examined the same four VEGF polymorphisms that we did, but
they found no associations with breast cancer risk. The differ-
ence in results between our study and the European study
could be due to chance. Alternatively, there are several notable
differences between the types of breast cancer cases
included that might have contributed to the differences in
results. First, in the European study only familial breast cancer
cases were used to examine the -1154G/A polymorphism,
which is the VEGF polymorphism most strongly associated
with invasive cancer in our study. Second, the European study
probably included a substantial number of premenopausal
breast cancer cases (the median age of the unselected Swed-
ish cases at diagnosis was 54 years), whereas our study
included only postmenopausal cases. Finally, in populations in
which detection of in situ breast cancer is common, women
carrying high expression VEGF alleles could be at increased
risk for invasive cancer because their breast cancers may be
more likely to progress rapidly enough to escape detection as
in situ cancer. This mechanism could have played an important
role in our study, in which approximately 20% of breast cancer
cases were diagnosed as in situ cancers (presumably due to
the high prevalence of mammographic screening [20]), but it
is unlikely to have been important in the European study pop-
ulation, in which detection of in situ breast cancers appears to
have been rare [19].
With respect to other previous studies, we did not observe the
increased risk for invasive cancer associated with the +936C
allele that was observed in an Austrian study [14]. The associ-
ation between the -1154G allele and breast cancer risk
observed in our study was not observed in a previous study
from the UK [15], although the UK study included only 134
breast cancer cases and had limited statistical power.
Because most breast cancer cases included in this analysis
were prevalent (diagnosed before the time of blood collec-
tion), it is important to consider the potential for survival bias.
Women with breast cancer in this cohort who did not survive
until the time when blood samples were collected could not be
included in the study. Therefore, if pro-angiogenic VEGF alle-
les are associated with reduced breast cancer survival, we
may have underestimated their effect on breast cancer inci-
dence. A recent Chinese study [21] reported that the -634G
allele was associated with reduced overall survival among
breast cancer patients, although there was no association with
breast cancer recurrence. However, important survival bias
appears unlikely in our cohort, given that survival rates from
breast cancer were quite high. Only 5% of breast cancer
cases diagnosed in the CPS-II Nutrition Cohort during the
years included in this analysis died from breast cancer before
Table 2
Odds ratios for invasive breast cancer incidence by VEGF 
promoter haplotype.
Haplotype copies Cases/controls OR (95% CI)
AAG
0 188/204 1.0 (ref.)
1 149/224 0.69 (0.51–0.92)
2 33/56 0.62 (0.38–1.00)
P (for trend) 0.008
AGG
0 260/342 1.0 (ref.)
1 98/133 0.97 (0.71–1.33)
2 12/9 1.71 (0.70–4.15)
P (for trend) 0.63
CGG
0 230/327 1.0 (ref.)
1 125/144 1.27 (0.94–1.72)
2 15/13 1.68 (0.78–3.61)
P (for trend) 0.054
CGC
0 161/220 1.0 (ref.)
1 170/217 1.07 (0.80–1.43)
2 39/47 1.18 (0.73–1.90)
P (for trend) 0.47
Haplotypes defined by polymorphisms at -2578, -1154, and -634 of 
the vascular endothelial growth factor gene. Includes 370 cases of 
invasive breast cancer and 484 controls with complete data on all 
three polymorphisms. Odds ratios (ORs) adjusted for birth year, year 
of blood draw, and race/ethnicity. CI, confidence interval.Breast Cancer Research    Vol 8 No 2    Jacobs et al.
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we completed blood collection in the cohort. The two largest
previous studies of VEGF polymorphisms and breast cancer
[15,19] also included prevalent breast cancer cases, and the
extent to which survival bias might have affected their results
is unclear.
The main limitation of the present study is that it is only of mod-
erate size. Larger studies will be needed to examine potentially
important differences by stage more thoroughly. Strengths of
the study include the potential functional importance of the
polymorphisms examined and the fact that we were able to
examine common haplotypes in the VEGF promoter region. To
our knowledge, this is the first study to examine specifically the
association between VEGF polymorphisms and in situ breast
cancer, although the number of in situ cancers in our study
was relatively small.
Conclusion
Our findings provide limited support for the hypothesis that the
-2578C and -1154G VEGF  alleles are associated with
increased risk for invasive breast cancer in postmenopausal
women. Any future studies of the association between VEGF
polymorphisms and breast cancer risk should examine
whether results differ for in situ and invasive breast cancers.
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